Loading...

Terkeltaub, Robert Dr.

Title(s)Professor, Medicine
SchoolRheumatology
Address9500 Gilman Drive #
La Jolla CA 92093
Phone858-552-8585
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    McGill University, Montreal, CanadaMD1976Medicine
    McGill University, Montreal, CanadaDCS1972Biology

    Collapse Overview 
    Collapse Overview
    Research Interests
    Cartilage nucleotide metabolism and disease; the regulation of proinflammatory cytokine expression in macrophages.

    Collapse Research 
    Collapse Research Activities and Funding
    Novel Synovial Role in Pathogenesis of Gout
    NIH/NIAMS R21AR075990Aug 1, 2019 - Jul 31, 2021
    Role: Principal Investigator
    Rheumatic Diseases Research Training Grant
    NIH/NIAMS T32AR064194May 9, 2013 - Apr 30, 2024
    Role: Principal Investigator
    Innate Inflammation in Osteoarthritis
    VA I01BX001660Apr 1, 2012 - Mar 31, 2021
    Role: Principal Investigator
    Transglutaminase 2 in Arterial Calcification and Atherosclerosis
    NIH/NHLBI R01HL087252May 15, 2008 - Feb 28, 2012
    Role: Principal Investigator
    Chondrocyte S100/Calgranulins and RAGE in Osteoarthritis
    NIH/NIAMS R01AR054135Jun 1, 2006 - May 31, 2010
    Role: Principal Investigator
    ANK and Joint Ankylosis in Spondylitis
    NIH/NIAMS R01AR049366Jan 1, 2005 - Nov 30, 2008
    Role: Principal Investigator
    Molecular Mechanisms in Arterial Calcification
    NIH/NHLBI R01HL077360Jul 1, 2004 - Jun 30, 2014
    Role: Principal Investigator
    PTHRP 1 to 173 IN CHONDROCYTES
    NIH/NIAMS R01AR047347Apr 6, 2001 - Jan 31, 2006
    Role: Principal Investigator
    MULTIPURPOSE ARTHRITIS &MUSCULOSKELETAL DISEASE CENTER
    NIH P60AR040770Aug 1, 1991 - Feb 28, 2002
    Role: Co-Investigator
    Studies of Joint Aging and Osteoarthritis
    NIH P01AG007996Dec 1, 1988 - Apr 30, 2017
    Role: Co-Investigator
    LOW DENSITY LIPOPROTEIN AND INFLAMMATION
    NIH/NIDDK R01DK036702Jul 1, 1985 - Jun 30, 1996
    Role: Principal Investigator
    LOW DENSITY LIPOPROTEINS AND GOUT
    NIH/NIADDK R23AM036702Jul 1, 1985 - Jun 30, 1988
    Role: Principal Investigator
    LOW DENSITY LIPOPROTEINS AND GOUT
    NIH/NIDDK R23DK036702Jul 1, 1985 - Jun 30, 1988
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. What makes gouty inflammation so variable? BMC Med. 2017 08 18; 15(1):158. Terkeltaub R. PMID: 28818081.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    2. Gout: multinational gout guidelines: how do we move beyond 'déjà vu'? Nat Rev Rheumatol. 2013 Oct; 9(10):567-9. Terkeltaub R. PMID: 24045709.
      View in: PubMed   Mentions:    Fields:    
    3. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011 Aug; 63(8):2226-37. Terkeltaub RA, Furst DE, Digiacinto JL, Kook KA, Davis MW. PMID: 21480191.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    4. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010 Apr; 62(4):1060-8. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. PMID: 20131255.
      View in: PubMed   Mentions: 85     Fields:    Translation:Humans
    5. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol. 2010 Jan; 6(1):30-8. Terkeltaub R. PMID: 20046204.
      View in: PubMed   Mentions: 88     Fields:    Translation:Humans
    6. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis. 2009 Oct; 68(10):1613-7. Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, Wu R, Mellis S, Radin A. PMID: 19635719.
      View in: PubMed   Mentions: 87     Fields:    Translation:Humans
    7. Gout. Novel therapies for treatment of gout and hyperuricemia. Arthritis Res Ther. 2009; 11(4):236. Terkeltaub R. PMID: 19664185.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    8. Gout Study Group: update on hyperuricemia and gout. Joint Bone Spine. 2009 Jul; 76(4):444-6. Terkeltaub R, Zelman D, Scavulli J, Perez-Ruiz F, Lioté F. PMID: 19559637.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    9. A sugar transporter regulates serum urate levels: implications for prevention and management of hyperuricemia in gout. Curr Rheumatol Rep. 2009 Apr; 11(2):83-6. Terkeltaub RA. PMID: 19296879.
      View in: PubMed   Mentions:    Fields:    
    10. Colchicine update: 2008. Semin Arthritis Rheum. 2009 Jun; 38(6):411-9. Terkeltaub RA. PMID: 18973929.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    11. Physiologic and pathologic functions of the NPP nucleotide pyrophosphatase/phosphodiesterase family focusing on NPP1 in calcification. Purinergic Signal. 2006 Jun; 2(2):371-7. Terkeltaub R. PMID: 18404477.
      View in: PubMed   Mentions: 27     Fields:    
    12. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther. 2006; 8 Suppl 1:S4. Terkeltaub R, Bushinsky DA, Becker MA. PMID: 16820043.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    13. Hyperuricemia treatment: is creatinine clearance a safer allopurinol dosing meter than plasma creatinine levels? Nat Clin Pract Rheumatol. 2006 Feb; 2(2):68-9. Terkeltaub R. PMID: 16932657.
      View in: PubMed   Mentions:    Fields:    
    14. Role of interleukin-8 in PiT-1 expression and CXCR1-mediated inorganic phosphate uptake in chondrocytes. Arthritis Rheum. 2005 Jan; 52(1):144-54. Cecil DL, Rose DM, Terkeltaub R, Liu-Bryan R. PMID: 15641067.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    15. Invited review: the mitochondrion in osteoarthritis. Mitochondrion. 2002 Feb; 1(4):301-19. Terkeltaub R, Johnson K, Murphy A, Ghosh S. PMID: 16120285.
      View in: PubMed   Mentions: 27     Fields:    
    16. Inorganic pyrophosphate generation and disposition in pathophysiology. . 2001 Jul; 281(1):C1-C11. Terkeltaub RA. PMID: 11401820.
      View in: PubMed   Mentions:
    17. Chemokines and atherosclerosis. Curr Opin Lipidol. 1998 Oct; 9(5):397-405. Terkeltaub R, Boisvert WA, Curtiss LK. PMID: 9812193.
      View in: PubMed   Mentions: 26     Fields:    Translation:Cells
    Robert's Networks
    Concepts (101)
    Derived automatically from this person's publications.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _
    ↑